Peter Margetts, McMaster University
Associate Professor
Department of Medicine
Hamilton, Ontario
margetts@mcmaster.ca
Office:
(905) 522-1155 ext. 32299
Bio/Research
I am investigating the pathology of tissue fibrosis pertaining to kidneys and the peritoneum. I am interested in cytokines, growth factors, and cells involved in the progression or maintenance of fibrosis; the role of angiogenesis in fibrosis; and gene therapy and pharmacologic techniques to inte...
Click to Expand >>
Click to Expand >>
Bio/Research
I am investigating the pathology of tissue fibrosis pertaining to kidneys and the peritoneum. I am interested in cytokines, growth factors, and cells involved in the progression or maintenance of fibrosis; the role of angiogenesis in fibrosis; and gene therapy and pharmacologic techniques to interfere with fibrosis.
I am specifically studying the process of epithelial mesenchymal transition in peritoneal fibrosis; a central process in the early stage of fibrosis. I am also interested in factors involved in the maintenance of fibrosis, including metalloproteinases and their inhibitors. I have been studying the role of transforming growth factor beta in angiogenesis and specifically the regulation of angiopoietins in fibrotic tissue. These studies have wide applicability to scar formation, and ischemic disease. We have used adenovirus mediated gene therapy to inhibit fibrosis and angiogenesis and are exploring other gene therapy techniques. I have also studied the use of novel pharmacologic agents for modulating the fibrogenic response; specifically the immunomodulatory agents rapamycin and mycophenolate.
We use adenovirus mediated gene transfer, animal models of renal disease and peritoneal fibrosis, transgenic animals, cell culture techniques, quantitative real time PCR, western blot, ELISA, zymography, histology, fluorescent and light immunohistochemistry, EM, and laser capture microdissection.
Click to Shrink <<
I am specifically studying the process of epithelial mesenchymal transition in peritoneal fibrosis; a central process in the early stage of fibrosis. I am also interested in factors involved in the maintenance of fibrosis, including metalloproteinases and their inhibitors. I have been studying the role of transforming growth factor beta in angiogenesis and specifically the regulation of angiopoietins in fibrotic tissue. These studies have wide applicability to scar formation, and ischemic disease. We have used adenovirus mediated gene therapy to inhibit fibrosis and angiogenesis and are exploring other gene therapy techniques. I have also studied the use of novel pharmacologic agents for modulating the fibrogenic response; specifically the immunomodulatory agents rapamycin and mycophenolate.
We use adenovirus mediated gene transfer, animal models of renal disease and peritoneal fibrosis, transgenic animals, cell culture techniques, quantitative real time PCR, western blot, ELISA, zymography, histology, fluorescent and light immunohistochemistry, EM, and laser capture microdissection.
Click to Shrink <<